+23%

est. 2Y upside i

HealthcareSeries A

Pacagen is house of brands focused on disrupting consumer industries through biotechnology-backed products built by our in-house research lab. We are actively incubating new technologies in the immune, inflammation, and consumer health spaces.

Rank

#1542

Sector

Biotechnology

Est. Liquidity

~5Y

Data Quality

Data: Low

This equity offers moderate expected upside (~23%) over 2 years but carries significant downside risk due to high incumbent competition and severe preference overhang.

Last updated: July 3, 2026

Bull (20%)+161%

Bull case: Pacagen achieves category leadership and IPO, sustaining 5x revenue multiple on $16.85M revenue, yielding $84.25M exit. 20% dilution reduces net upside to 160.8%.

Base (35%)+20%

Base case: Multiple compresses to 2.5x inline with consumer staples, exit value $42.1M. After 20% dilution, net upside 20.4%.

Bear (45%)-36%

Bear case: Incumbent competition and regulatory issues compress multiple to 1.5x, exit $25.3M. After preference and dilution, net downside -35.8%.

Est. time to liquidity~5.0 years

Preference Stack Risk

severe

Funding Intensity

21670%

$13M in preferred stock represents 43% of the estimated $30M valuation, meaning common stock is junior to a large preference.

Dilution Risk

high

With $13M in funding and no profitability, another round within 24 months is likely, diluting current equity by ~20%.

Secondary Liquidity

none

No secondary market activity; no secondary implied valuation available.

Questions to Ask at the Interview

Strategic questions based on Pacagen's data — designed to show you've done your homework.

  • 1

    “How does Pacagen plan to differentiate from Pro Plan LiveClear and Clorox Pure given their distribution advantages?”

  • 2

    “What is the unit economics (CAC, LTV, churn) for the subscription model?”

  • 3

    “Given the early stage and limited liquidity options, what is the expected timeline to an exit event?”

Community

Valuation Sentiment

Our model estimates +23% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.